Today, over 60 million women worldwide use the Pill for contraception ... in the US under its own name and using its own Bayer Cross corporate logo. This was under the leadership of Dr Manfred ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid generic competition, wrote Connor Hart for the Wall ...

Despite restructuring efforts, Bayer's financial outlook for 2025 remains weak, with anticipated declining earnings. Consensus estimates project $3-4 billion free cash flow for 2026-2027 ...

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of €33.00. The company’s shares closed last Tuesday at ...

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.

In the United States, Bayer will continue its multipronged strategy to significantly contain the Roundup™ litigation. Having achieved favorable outcomes in 15 of the last 22 trials, the company ...

Bayer argues PCB levels were safe, blames school for ignoring warnings Previous trials resulted in over $1.5 billion in verdicts Jan 14 (Reuters) - A Washington jury on Tuesday ordered Bayer ...

Bayer AG’s Monsanto unit stopped making toxic PCBs a half century ago, but the legal fallout lingers even as many of the building materials made with the chemicals are no longer used in US homes ...

The waterproof Beats Pill portable speaker everyone loves is down to $99.99, and you can save up to $250 on the M3 MacBook Air 15-inch, depending on your build. You’ll find those great deals and ...

Combination birth control pills, or the pill for short, are oral contraceptives that prevent pregnancy. If you’re considering your birth control options, the pill is one of the most common and ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...